- Home
- DCPH
as 05-20-2024 2:34pm EST
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.2B | IPO Year: | 2017 |
| Target Price: | $24.17 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.90 - $25.55 | Next Earning Date: | 05-10-2024 |
| Revenue: | $174,910,000 | Revenue Growth: | 26.51% |
| Revenue Growth (this year): | 25.05% | Revenue Growth (next year): | 28.04% |
Share on Social Networks:
Stock Insider Trading Activity of Deciphera Pharmaceuticals Inc. (DCPH)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Martin Daniel C. | DCPH | Chief Commercial Officer | Feb 15 '24 | Sell | $15.62 | 2,267 | $35,405.10 | 55,118 | SEC Form 4 |
| Sherman Matthew L | DCPH | EVP & Chief Medical Officer | Feb 15 '24 | Sell | $15.62 | 2,615 | $40,840.29 | 108,739 | SEC Form 4 |
| Pitman Jama | DCPH | SVP, Chief Development Officer | Feb 15 '24 | Sell | $15.62 | 2,267 | $35,405.10 | 68,031 | SEC Form 4 |
| Kelly Thomas Patrick | DCPH | Chief Financial Officer | Jan 16 '24 | Sell | $14.47 | 2,435 | $35,233.96 | 66,085 | SEC Form 4 |
| Martin Daniel C. | DCPH | Chief Commercial Officer | Jan 16 '24 | Sell | $14.47 | 1,624 | $23,498.79 | 47,660 | SEC Form 4 |
| Pitman Jama | DCPH | SVP, Chief Development Officer | Jan 16 '24 | Sell | $14.47 | 1,624 | $23,498.96 | 50,573 | SEC Form 4 |
| Hoerter Steven L. | DCPH | President and CEO | Dec 12 '23 | Sell | $15.37 | 30,664 | $471,216.75 | 72,763 | SEC Form 4 |
| Kelly Thomas Patrick | DCPH | Chief Financial Officer | Dec 12 '23 | Sell | $15.37 | 2,792 | $42,904.94 | 68,520 | SEC Form 4 |
| Martin Daniel C. | DCPH | Chief Commercial Officer | Dec 12 '23 | Sell | $15.37 | 1,727 | $26,538.98 | 49,284 | SEC Form 4 |
| Martin Daniel C. | DCPH | Chief Commercial Officer | Nov 30 '23 | Sell | $12.57 | 17,801 | $223,755.01 | 45,435 | SEC Form 4 |
| Pitman Jama | DCPH | See Remarks | Oct 28 '23 | Sell | $12.02 | 1,407 | $16,908.76 | 48,283 | SEC Form 4 |
| Kelly Thomas Patrick | DCPH | Chief Financial Officer | Oct 28 '23 | Sell | $12.02 | 2,316 | $27,832.76 | 63,068 | SEC Form 4 |
Latest Deciphera Pharmaceuticals Inc. News
DCPH Breaking Stock News: Dive into DCPH Ticker-Specific Updates for Smart Investing
Zacks
10 days ago
Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
Zacks
10 days ago
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
Zacks
17 days ago
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Zacks
18 days ago
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
MT Newswires
20 days ago
Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26
MT Newswires
20 days ago
Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60
MT Newswires
20 days ago
JMP Downgrades Deciphera Pharmaceuticals to Market Perform
Reuters
20 days ago